使用18F-AlF或冷试剂盒68Ga标记的FAPI-74 PET/CT:肺癌患者的生物分布、辐射剂量学与肿瘤勾画
在10例肺癌患者中,18F-FAPI-74 PET在注射后1小时于原发灶、淋巴结和远处转移灶获得最高对比度,SUVmax超过10。18F-FAPI-74每100 MBq有效剂量为1.4 ± 0.2 mSv,68Ga-FAPI-74为1.6 mSv。FAPI PET/CT支持引导放疗的靶区定义。
要点
- 18F-FAPI-74 PET在注射后1小时于原发灶、淋巴结及远处转移灶对比度最高,SUVmax超过10。
- 18F-FAPI-74每100 MBq有效剂量为1.4 ± 0.2 mSv,68Ga-FAPI-74为1.6 mSv。
- FAPI PET/CT支持引导放疗的靶区定义。
核心结论
- FAPI-74 PET/CT的高对比度和低辐射负担有利于多种临床应用。
- 18F-FAPI-74的集中大规模生产或68Ga-FAPI-74的分散式冷试剂盒标记允许灵活的常规使用。
研究设计与样本
- 在10例肺癌患者中,注射259 ± 26 MBq的18F-FAPI-74后于10分钟、1小时和3小时采集PET扫描。
- 基于各时间点SUV半定量评估生理生物分布和肿瘤摄取。
- 使用OLINDA/EXM 1.1版及QDOSE剂量学软件配合IDAC-Dose 2.1版剂量计算器评估吸收剂量。
- 采用相同方法评估一例注射263 MBq的68Ga-FAPI-74后的检查。
主要发现
- 注射18F-FAPI-74后1小时,原发灶、淋巴结和远处转移灶获得最高对比度,SUVmax超过10。
- 18F-FAPI-74每100 MBq给药活度的有效剂量为1.4 ± 0.2 mSv,68Ga-FAPI-74为1.6 mSv。
- 诊断性18F-FAPI-74 PET扫描的辐射负担甚至低于18F-FDG和其他18F示踪剂的PET扫描;68Ga-FAPI-74与其他68Ga配体相当。
- FAPI PET/CT支持引导放疗的靶区定义。
临床怎么用
- 原文结论指出FAPI-74 PET/CT的高对比度和低辐射负担有利于多种临床应用。
- 原文结论指出18F-FAPI-74的集中大规模生产或68Ga-FAPI-74的分散式冷试剂盒标记允许灵活的常规使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
68Ga-fibroblast activation protein inhibitors (FAPIs) 2, 4, and 46 have already been proposed as promising PET tracers. However, the short half-life of 68Ga (68 min) creates problems with manufacture and delivery. 18F (half-life, 110 min) labeling would result in a more practical large-scale production, and a cold-kit formulation would improve the spontaneous availability. The NOTA chelator ligand FAPI-74 can be labeled with both 18F-AlF and 68Ga. Here, we describe the in vivo evaluation of 18F-FAPI-74 and a proof of mechanism for 68Ga-FAPI-74 labeled at ambient temperature. Methods: In 10 patients with lung cancer, PET scans were acquired at 10 min, 1 h, and 3 h after administration of 259 ± 26 MBq of 18F-FAPI-74. Physiologic biodistribution and tumor uptake were semiquantitatively evaluated on the basis of SUV at each time point. Absorbed doses were evaluated using OLINDA/EXM, version 1.1, and QDOSE dosimetry software with the dose calculator IDAC-Dose, version 2.1. Identical methods were used to evaluate one examination after injection of 263 MBq of 68Ga-FAPI-74. Results: The highest contrast was achieved in primary tumors, lymph nodes, and distant metastases at 1 h after injection, with an SUVmax of more than 10. The effective dose per a 100-MBq administered activity of 18F-FAPI-74 was 1.4 ± 0.2 mSv, and for 68Ga-FAPI-74 it was 1.6 mSv. Thus, the radiation burden of a diagnostic 18F-FAPI-74 PET scan is even lower than that of PET scans with 18F-FDG and other 18F tracers; 68Ga-FAPI-74 is comparable to other 68Ga ligands. FAPI PET/CT supported target volume definition for guiding radiotherapy. Conclusion: The high contrast and low radiation burden of FAPI-74 PET/CT favor multiple clinical applications. Centralized large-scale production of 18F-FAPI-74 or decentralized cold-kit labeling of 68Ga-FAPI-74 allows flexible routine use.
引用
- Giesel FL, Adeberg S, Syed M, et al. FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients. J Nucl Med. 2020. PMID: 32591493. doi:10.2967/jnumed.120.245084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。